首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

2018966

對雙特異性抗體藥物複合體（BsADCs）的全球臨床試驗、監管核准、開發平台和市場機會的洞察（2026 年）

Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals, Development Platforms & Market Opportunity Insight 2026

出版日期: 2026年04月01日 | 出版商:

KuicK Research | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

「2026年全球雙特異性抗體藥物複合體（BsADC）臨床試驗、監管核准、開發平台和市場機會洞察」報告的亮點和發現：

調查方法
預計首個雙特異性抗體藥物複合體（BsADC）將於 2028 年獲得市場核准。
對超過 150 項 BsADC 臨床試驗進行了全面分析，按公司、國家、適應症、臨床階段和優先順序進行分類。
中國在雙特異性抗體藥物複合體研發方面主導：已完成100多項臨床試驗。
到2030年，雙特異性抗體藥物複合體市場的市場機會：超過20億美元
本公司對雙特異性抗體藥物複合體(BsADC) 技術平台的分析
競爭格局

雙特異性抗體藥物複合體的必要性及本報告的意義

雙特異性抗體藥物複合體）作為抗體藥物複合體的演進型藥物，代表了結合雙特異性抗體優勢的下一代抗體療法。這些分子能夠針對兩個不同的靶點，從而應對癌症治療中一些最迫切的挑戰。儘管腫瘤微環境的異質性限制了單株抗體和抗體藥物複合體在癌症治療的應用，但BsADCs有望提供更完善的解決方案。

截至2026年4月，全球生物特異性抗體藥物偶聯物（BsADC）市場尚處於早期階段，但發展迅速，擁有強大且不斷擴展的研發管線，儘管後期研發項目有限。候選藥物如isarontamab/brengitecan（Iza-bren，BL-B01D1）已完成臨床概念驗證（PoC），顯示其具有臨床成功潛力和未來商業化前景。

本報告整合了科學、臨床、技術和商業性觀點，全面概述了 BsADC 市場，並為策略決策提供支援。

報告中包含了對臨床試驗的深入分析。

臨床開發是生物活性藥物偶聯物（BsADC）市場成長的主要驅動力，產品線正迅速擴展，涵蓋早期、中期和晚期開發階段。腫瘤學仍然是主要關注領域，BsADC正在骨髓惡性腫瘤和固態腫瘤中進行評估，尤其是在復發或難治性疾病患者群體中。

後期候選藥物的正向臨床結果進一步增強了人們對這類療法的整體信心。例如，Iza-bren 在轉移性三陰性乳癌中顯示出良好的無惡化生存期和總存活期療效，並且在 EGFR 突變陽性的非小細胞肺癌中也顯示出較高的緩解率。同樣，JSKN003 目前正在進行 HER2 陽性乳癌的 III 期臨床試驗，即使在 HER2 表達水平低或異質性較高的患者中也顯示出良好的療效。

本報告也詳細分析了處於各個研發階段的在研臨床試驗，探討了臨床試驗設計、目標病患群體、劑量和合併用藥策略等多個面向。免疫查核點抑制劑與化療藥物聯合治療的日益普及表明，癌症治療正朝著更綜合化的方向發展，而多個後期候選藥物的進展也清晰地展現了生物活性藥物偶聯物（BsADC）研發管線的成熟度。

專注於雙特異性抗體藥物複合體研發的主要企業

生物活性藥物偶聯物（BsADC）市場的發展主要得益於傳統製藥公司和生物技術行業新參與企業的積極參與。四川百利藥業、SystImmune等公司目前在先進分子藥物（如Iza-bren）的研發方面處於市場領先地位，而Alphamab Oncology則憑藉JSKN003、JSKN033和JSKN027等新型分子藥物進一步深化了市場。

新參與企業在推動生物靶向抗體藥物偶聯物（BsADC）市場發展方面也發揮著重要作用。 Avenzo Therapeutics、Duality Bio、InduPro 等新參與企業憑藉 AVZO-103、DB-1418 和 IDP-001 等新型分子引領市場，這些分子旨在透過雙重抗原靶向來應對腫瘤生物學的複雜性。其他新參與企業，例如科倫生物，也憑藉 SKB103 和 SKB571 等分子引領市場。

一份概述雙特異性抗體藥物複合體片段未來發展方向的報告。

受雙特異性抗體藥物複合體（BsADC）在臨床試驗中取得成功、技術進步以及該領域投資的推動，BsADC市場預計在未來幾年將迎來顯著成長。隨著BsADC在臨床試驗中不斷取得進展，它們有望成為一類新型標靶治療。

聯合治療有望在塑造生物特異性抗體藥物偶聯物（BsADCs）的未來發展中發揮關鍵作用。尤其是在腫瘤領域，聯合療法可與免疫療法和其他標靶治療合併使用，以改善臨床療效。進一步探索其他疾病領域可望拓寬BsADCs的治療前景。

總之，在強大的產品平臺、技術進步和策略合作的支持下，雙特異性抗體藥物複合體有望徹底改變精準醫療和標靶治療的未來。

Research Methodology
First Bispecific Antibody Drug Conjugate (BsADC) Market Approval Expected By 2028
Comprehensive Insight On More Than 150 BsADC In Clinical Trials By Company, Country, Indication, Phase & Priority Status
China Dominating Bispecific Antibody Drug Conjugate Development: > 100 Clinical Trials
Bispecific Antibody Drug Conjugate Market Opportunity By 2030: > USD 2 Billion
Insight On Bispecific Antibody Drug Conjugates Technologies Platforms By Companies
Competitive Landscape

Need For Bispecific Antibody Drug Conjugates & Why This Report?

Bispecific antibody drug conjugates are emerging as the next generation of antibody based therapies as an evolution of antibody drug conjugates, with the added advantage of bispecific antibodies. These molecules have the ability to target two different targets, enabling them to address some of the most pressing issues in the treatment of cancers. With the limitations of monoclonal antibodies and antibody drug conjugates in the treatment of cancers due to the heterogeneity of the tumor microenvironment, BsADCs are poised to offer more refined solutions to the treatment of cancers.

As of April 2026, the global BsADC market remains in a relatively early but rapidly advancing stage, with limited late stage assets but a strong and expanding pipeline. Candidates such as Izalontamab brengitecan (Iza-bren, BL-B01D1) are demonstrating clinical proof-of-concept, indicating the potential for both clinical success and future commercialization.

This report provides a comprehensive overview of the BsADC market, integrating scientific, clinical, technological, and commercial perspectives to support strategic decision making.

Clinical Trials Insight Included In Report

Clinical development is a major driver of growth in the BsADC market, with a rapidly expanding pipeline across early, mid, and late stages of development. Oncology remains the primary focus, where BsADCs are being evaluated in both hematological malignancies and solid tumors, with particular emphasis on patient populations with relapsed or refractory disease.

The positive clinical results from late-stage candidates are further adding to the overall confidence in this therapeutic class. For example, Iza-bren has shown positive results in terms of progression-free survival and overall survival in metastatic triple-negative breast cancer, and response rates in EGFR mutant non-small cell lung cancer. Similarly, JSKN003 is currently in Phase III trials for HER2-positive breast cancer and has also shown positive results even in patients with low or heterogeneous HER2 expression levels.

The report also includes a detailed analysis of clinical trials currently underway, including those in all phases of development, and discusses various aspects such as clinical trial design, patient population, dose and combination strategies, and so on. The increased focus on combination therapies with immune checkpoint inhibitors and chemotherapy agents also indicates a shift toward a more combined approach in cancer therapies, and the progress of several candidates in late-stage development also speaks volumes for the maturity of the BsADC pipeline.

Major Companies Active In R&D Of Bispecific Antibody Drug Conjugates

The BsADC market has been driven by the active engagement of both traditional pharmaceutical companies and new entrants in the biotechnology industry. Sichuan Baili Pharmaceutical, SystImmune, and other companies are currently the market leaders in the development of advanced molecules, including Iza-bren, while Alphamab Oncology continues to enhance the depth of the market with new molecules, including JSKN003, JSKN033, and JSKN027.

New entrants are also playing an instrumental role in propelling the BsADC market forward. Avenzo Therapeutics, Duality Bio, InduPro, and other new entrants are driving the market with new molecules, including AVZO-103, DB-1418, and IDP-001, which are designed to address the complexities of tumor biology through dual-antigen targets. Other new entrants, including Kelun-Biotech, are driving the market with molecules, including SKB103 and SKB571.

Report Indicating Future Direction Of Bispecific Antibody Drug Conjugate Segment

The bispecific antibody drug conjugate market is expected to grow considerably in the coming years, driven by the success of bispecific antibody drug conjugates in clinical trials, technology advancements, and investments in the field. As bispecific antibody drug conjugates continue to progress in clinical trials, they are expected to emerge as a new class of targeted therapies.

Combination therapy is expected to play a critical role in shaping the future of BsADCs, particularly in oncology, where they may be used alongside immunotherapies and other targeted agents to improve clinical outcomes. Expanding research into additional disease areas may further broaden the therapeutic potential of BsADCs.

In conclusion, bispecific antibody drug conjugates, driven by a strong product pipeline, technology advancements, and strategic partnerships, are expected to revolutionize the future of precision medicine and targeted therapies.

1. Conception & Ongoing Development Of Bispecific Antibody Drug Conjugates

1.1 Overview
1.2 Comparison With Other Immunotherapies

2. Need For Bispecific Antibody Drug Conjugates

3. Bispecific Antibody Drug Conjugates - Design & Mechanism Of Action

3.1 General Structure & Design
3.2 Mechanism Of Action

4. Global Bispecific Antibody Drug Conjugate Market Insight

4.1 Current Market Scenario
4.2 Future Market Opportunity

5. Bispecific Antibody Drug Conjugates Market Analysis by Region

5.1 China
5.2 US
5.3 Europe
5.4 South Korea

6. Bispecific Antibody Drug Conjugates - Application & Development By Indication

6.1 Breast Cancer
6.2 Gastrointestinal Cancer
6.3 Lung Cancer
6.4 Urologic Cancers
6.5 Gynecologic Cancers

7. Global Bispecific Antibody Drug Conjugates Clinical Trials Overview

7.1 By Phase
7.2 By Company
7.3 By Country
7.4 By Indication

8. Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III
8.7 Preregistration

9. Bispecific Antibody Drug Conjugates Technologies Platforms By Companies

10. Competitive Landscape

10.1 Almac Discovery
10.2 Alphamab Oncology
10.3 Amgen
10.4 AskGene Pharma
10.5 AstraZeneca
10.6 Beijing Biocytogen
10.7 BiVictriX Therapeutics
10.8 Bright Biologics
10.9 Corellia AI
10.10 CStone Pharmaceuticals
10.11 Debiopharm
10.12 Doma Bio
10.13 DualityBio
10.14 Enduring Biotech
10.15 Genmab
10.16 InduPro
10.17 Innovent Biologics
10.18 Kanaph Therapeutics
10.19 ProEn Therapeutics
10.20 SystImmune

簡介目錄圖表

List of Figures

Figure 1-1: Future Directions In BsADC Development
Figure 1-2: Limitations Of Convectional Immunotherapies Addressable By BsADCs
Figure 3-1: Bispecific Antibody Drug Conjugate - General Structure
Figure 3-2: Bispecific Antibody Drug Conjugate - General Mechanism of Action
Figure 4-1: Bispecific Antibody Drug Conjugate Market Forecast - Projections for First 12 & 24 Months Post Approval Of First Drug (US$ Million)
Figure 4-2: Key Future Opportunities
Figure 6-1: BL-B01D1-306 Phase III (NCT06343948) Study - Initiation & Estimated Completion Year
Figure 6-2: BL-B01D1-307 Phase III (NCT06382142) Study - Initiation & Estimated Completion Year
Figure 6-3: BL-B01D1-204-04 Phase II (NCT06471205) Study - Initiation & Estimated Completion Year
Figure 6-4: BL-B01D1-LUNG-101 Phase I (NCT05983432) Study - Initiation & Estimated Completion Year
Figure 6-5: BL-B01D1-104 Phase I (NCT05470348) Study - Initiation & Estimated Completion Year
Figure 6-6: KM501-1001 Phase I (NCT05804864) Study - Initiation & Estimated Completion Year
Figure 6-7: JSKN016-202 Phase I/II (NCT06942234) Study - Initiation & Estimated Completion Year
Figure 6-8: BL-B01D1-SI-B003-201-05 Phase II (NCT06008054) Study - Initiation & Estimated Completion Year
Figure 6-9: BL-B01D1-103 Phase I (NCT05262491) Study - Initiation & Estimated Completion Year
Figure 6-10: BL-B01D1-302 Phase III (NCT06382129) Study - Initiation & Estimated Completion Year
Figure 6-11: BL-B01D1-301 Phase III (NCT06382116) Study - Initiation & Estimated Completion Year
Figure 6-12: BL-B01D1-304 Phase III (NCT06500026) Study - Initiation & Estimated Completion Year
Figure 6-13: IZABRIGHT-Lung01 Phase II/III (NCT07100080) Study - Initiation & Estimated Completion Year
Figure 6-14: AVENTINE-1 Phase I/II (NCT07038343) Study - Initiation & Estimated Completion Year
Figure 6-15: DM001001 Phase II (NCT06475937) Study - Estimated Initiation & Estimated Completion Year
Figure 6-16: EGRET Phase I (NCT05647122) Study - Estimated Initiation & Estimated Completion Year
Figure 6-17: BL-B01D1-201 Phase II (NCT05785039) Study - Initiation & Estimated Completion Year
Figure 6-18: BL-B01D1-102 Phase I (NCT05393427) Study - Initiation & Estimated Completion Year
Figure 6-19: IZABRIGHT-Bladder01 Phase II/III (NCT07106762) Study - Initiation & Estimated Completion Year
Figure 6-20: AVZO-103-1001 Phase I/II (NCT07193511) Study - Initiation & Estimated Completion Year
Figure 6-21: BL-B01D1-SI-B003-201-08 Phase II (NCT05990803) Study - Initiation & Estimated Completion Year
Figure 6-22: BL-B01D1-202 Phase Ib/II (NCT05803018) Study - Initiation & Estimated Completion Year
Figure 6-23: IMGN151-1001 Phase I (NCT05527184) Study - Initiation & Estimated Completion Year
Figure 6-24: JSKN003-102 Phase I/II (NCT05744427) Study - Initiation & Estimated Completion Year
Figure 7-1: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Phase (Numbers), 2026
Figure 7-2: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Company (Numbers), 2026
Figure 7-3: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Country (Numbers), 2026
Figure 7-4: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Indication (Numbers), 2026
Figure 9-1: ArbeleBio - Unnamed ADC Platform
Figure 9-2: BiVictriX - Bi-Cygni Therapeutics
Figure 9-3: Duality Biologics - DITAC Platform
Figure 9-4: Duality Biologics - DITAC Platform
Figure 9-5: LigaChem Biosciences - ConjuALL
Figure 9-6: LigaChem Biosciences - Conjugation Method
Figure 9-7: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-8: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-9: ProEn Therapeutics - ArtBody(TM) ADC technology
Figure 9-10: Synaffix - Proprietary Technologies